MEVPRO-2

• Research type

  Research Study

• Full title

  A phase 3, randomized, double blind, placebo controlled study of PF-06821497 (mevrometostat) with enzalutamide in metastatic castration resistant prostate cancer (MEVPRO-2)

• IRAS ID

  1010774

• Contact name

  Cheryl Becker

• Contact email

  cheryl.becker2@pfizer.com

• Sponsor organisation

  Pfizer Inc.

• Clinicaltrials.gov Identifier

  NCT06629779

• Research summary

  This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

• REC name

  West of Scotland REC 1

• REC reference

  24/WS/0155

• Date of REC Opinion

  7 Feb 2025

• REC opinion

  Further Information Favourable Opinion